Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-cell Guided Letermovir Discontinuation for CMV Prevention in allo-HSCT
NCT07569653Phase 4Recruiting
- Sponsor
- WeiShi Biological
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by WeiShi Biological. Primary endpoint: Incidence of Clinically Significant CMV Infection at 200 days. Started Oct 2025; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07569653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569653.